MREO
Mereo BioPharma Group Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.29
−4.08%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 500.0K | — | 10.0M | — |
| Cost of Revenue | 896.6K | 133.0K | — | 2.6M | (1.1M) |
| Gross Profit | (896.6K) | 367.0K | — | 7.4M | 1.1M |
| Operating Expenses | |||||
| R&D Expense | 14.6M | 17.8M | — | 17.4M | 29.5M |
| SG&A Expense | 18.9M | 23.0M | — | 18.4M | 26.1M |
| General & Admin Expense | 15.3M | 23.0M | — | 18.4M | 26.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (166.2K) | (2.1M) | — | — | — |
| Total Operating Expenses | 33.3M | 38.6M | — | 35.8M | 55.6M |
| Cost and Expenses | 34.2M | 38.8M | — | 38.4M | 54.4M |
| Operating Income (EBIT) | (34.2M) | (38.3M) | — | (28.4M) | (54.4M) |
| Non-Operating | |||||
| Interest Income | 1.5M | 2.2M | — | 2.1M | 840.0K |
| Interest Expense | 86.8K | 255.0K | — | 2.9M | 4.2M |
| Net Interest Income | 1.4M | 1.9M | — | (750.0K) | (3.3M) |
| Other Non-Op Income/Expense | 5.5M | (3.6M) | — | (1.6M) | 11.5M |
| Non-Operating Income (excl Interest) | (187.0K) | 3.4M | — | (1.3M) | (15.7M) |
| EBT (Pre-Tax Income) | (28.6M) | (41.9M) | — | (30.0M) | (42.9M) |
| Income Tax Expense | (567.2K) | — | — | (532.0K) | (718.0K) |
| Bottom Line | |||||
| Net Income | (28.1M) | (41.9M) | — | (29.5M) | (42.2M) |
| Earnings from Cont. Ops | (28.1M) | (41.9M) | — | (29.5M) | (42.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (28.1M) | (41.9M) | — | (29.5M) | (42.2M) |
| Per Share | |||||
| Basic EPS | ($0.18) | ($0.26) | $0.00 | ($1,100.22) | ($1.80) |
| Diluted EPS | ($0.37) | ($0.26) | $0.00 | ($1,100.22) | ($1.80) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.08 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 160.7M | 159.4M | 29.6M | 131.9M | 22.8M |
| Diluted Shares Outstanding | 160.7M | 159.4M | 29.6M | 131.9M | 22.8M |
| Profitability Metrics | |||||
| EBITDA | (32.7M) | (40.5M) | 1.1M | (26.1M) | (37.9M) |
| D&A | 1.3M | 1.1M | 1.1M | 1.1M | 889.0K |
| EBIT | (34.0M) | (41.6M) | — | (27.1M) | (38.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026